** Wall Street brokerages start coverage of insulin device maker, Beta Bionics BBNX.O, on a bullish note as IPO research quiet period ends
** Stifel starts coverage with "buy" rating and $25 PT, a 20% upside to the stock's last close
** Brokerage says the market for insulin-dependent diabetes is still large and has room for growth
** Co is a "serial innovator with a robust pipeline," including a patch and a bihormonal pump that delivers both glucagon and insulin. This pipeline has the potential to disrupt the market over the next five years, say Stifel analysts
** Piper Sandler starts coverage with "overweight" rating and $26 PT, a 22% upside to the stock's last close
** "We believe the upcoming type 2 diabetes approval and patch pump in 2027 is a robust opportunity that can further accelerate revenue"- Piper Sandler
** BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street were the underwriters for the IPO
** Stock has fallen 14.9% since its Nasdaq debut on 30 January
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.